We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is BioTelemetry (BEAT) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of BioTelemetry (BEAT - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
BioTelemetry is one of 833 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. BEAT is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for BEAT's full-year earnings has moved 4.68% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that BEAT has returned about 13.09% since the start of the calendar year. At the same time, Medical stocks have gained an average of 10.05%. This means that BioTelemetry is outperforming the sector as a whole this year.
Looking more specifically, BEAT belongs to the Medical Services industry, which includes 30 individual stocks and currently sits at #93 in the Zacks Industry Rank. On average, this group has gained an average of 14.29% so far this year, meaning that BEAT is slightly underperforming its industry in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track BEAT. The stock will be looking to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is BioTelemetry (BEAT) Outperforming Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of BioTelemetry (BEAT - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
BioTelemetry is one of 833 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. BEAT is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for BEAT's full-year earnings has moved 4.68% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that BEAT has returned about 13.09% since the start of the calendar year. At the same time, Medical stocks have gained an average of 10.05%. This means that BioTelemetry is outperforming the sector as a whole this year.
Looking more specifically, BEAT belongs to the Medical Services industry, which includes 30 individual stocks and currently sits at #93 in the Zacks Industry Rank. On average, this group has gained an average of 14.29% so far this year, meaning that BEAT is slightly underperforming its industry in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track BEAT. The stock will be looking to continue its solid performance.